Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 16.5% - Octapharma

Drug Profile

Immune globulin 16.5% - Octapharma

Alternative Names: Cutaquig; Gammanorm; IGIM-Octapharma; IGSC-Octapharma; Octanorm

Latest Information Update: 17 Sep 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Octapharma
  • Developer Aarhus Universitetshospital; Octapharma; Rigshospitalet
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immunodeficiency disorders
  • No development reported Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease
  • Discontinued Dermatomyositis

Most Recent Events

  • 09 Jun 2020 Octapharma completes a phase III trial in Immunodeficiency disorders in the US, Canada, Czech Republic, Hungary, Poland, Russia and Slovakia (NCT01888484) (EudraCT2013-003877-87)
  • 29 May 2020 Octapharma & BioMatrix plans a clinical trial for COVID-19-associated myocardial dysfunction (Combination therapy)
  • 17 Oct 2019 Octapharma initiates enrolment in a phase III trial for Immunodeficiency disorders in USA (NCT03939533)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top